Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBT (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBT for 6 consecutive years, with -$54.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 27.74% to -$54.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$275.7 million, a 18.36% increase, with the full-year FY2025 number at -$275.7 million, up 18.36% from a year prior.
  • EBT was -$54.9 million for Q4 2025 at Relay Therapeutics, up from -$74.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$42.2 million in Q1 2021 to a low of -$193.4 million in Q2 2021.
  • A 5-year average of -$80.5 million and a median of -$76.4 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 623.78% in 2021, then surged 60.29% in 2022.
  • Relay Therapeutics' EBT stood at -$67.5 million in 2021, then fell by 0.03% to -$67.5 million in 2022, then dropped by 23.74% to -$83.5 million in 2023, then grew by 8.97% to -$76.0 million in 2024, then grew by 27.74% to -$54.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EBT are -$54.9 million (Q4 2025), -$74.0 million (Q3 2025), and -$69.7 million (Q2 2025).